Latest News
Halozyme Therapeutics, Inc.
- Halozyme Therapeutics stock hits all-time high at 125.53 USD By Investing.com
- Halozyme Therapeutics, Inc. Estimates – FWB:RV7
- Halozyme Therapeutics Stock: 6 Straight Green Days, Up 14%
- Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
- Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability
- Halozyme wins court order to block Merck's injected Keytruda in select European markets
- Halozyme Wins Keytruda SC Patent Ruling
- Dutch court bars Merck's Keytruda SC in eight European markets in Halozyme patent case
- Why is Halozyme Therapeutics stock climbing today?
- Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
- Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup
- Halozyme appoints Jim Daly to board of directors By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →